Healthcare, Pharma & Life Sciences

Eagan – October 12, 2026 -- Solventum (NYSE: SOLV) will publish its second quarter fiscal 2026 financial results on Wednesday, August 5, 2026, after U.S. financial markets close.

Management to host webcast after the release

Solventum management will hold a webcast following the release to discuss the results. The company said other forward-looking and material information may also be covered during the call, so the session could contain disclosures beyond the quarterly figures.

Replay, slides and supplemental data to go online

A webcast replay, the earnings press release, presentation slides and supplemental financial disclosures will be available in the Investor Relations section of Solventum's website.

The announcement did not include financial guidance or preliminary figures for the quarter.

Eagan, Minn. – October 12, 2026 -- Solventum (NYSE: SOLV) said it intends to separate its Health Information Systems business, a healthcare software unit with $1.4 billion in annual sales, and is targeting completion within 12 to 18 months.

The move is the latest step in the company's three-phase transformation strategy. Solventum's Board of Directors and management expect the separation to leave a dedicated MedTech company focused on its MedSurg and Dental Solutions businesses.

Solventum weighs independent, combined or other deal structures

The company is evaluating several separation alternatives: an independent company, a combination with a scaled player in the space, or another transaction. It said it will pursue the structure it believes maximizes shareholder value.

Eagan, Minn. – October 12, 2026 -- Solventum raised its full-year 2026 adjusted EPS guidance to $7.10-$7.20 and announced its intent to separate its Health Information Systems business, after second-quarter organic sales rose 9.5%.

Organic sales climb 9.5% while reported sales rise 2.2% to $2.2 billion

Second-quarter sales reached $2.2 billion, up 2.2% on a reported basis. Solventum attributed the organic gain primarily to volume and product mix, with all reportable segments performing strongly. The organic figure also includes the expected benefit of advance orders placed ahead of ERP cutovers.

GAAP diluted EPS was $0.53. Adjusted diluted EPS reached $2.55, a 50.9% increase.

Eagan, Minnesota – October 12, 2026 -- Solventum (NYSE: SOLV) will present at the Wells Fargo Healthcare Conference on Wednesday, Sept. 9, 2026, with management taking part in a fireside chat beginning at approximately 10:15 a.m. EDT in Boston, Massachusetts.

Solventum management gets a 10:15 a.m. EDT slot in Boston on Sept. 9

The company announced the appearance on Sept. 2, 2026, one week before the session. The announcement did not name the executives who will take part or list agenda topics.

A live webcast and an archived replay of the fireside chat will be available on the company's investor relations website, giving investors who cannot attend in Boston access to the discussion.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will report its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

Management hosts call at 4:30 p.m. ET on results day

The interventional MRI (iMRI) company will hold a conference call at 4:30 p.m. ET on August 6 to review the quarter's results and discuss business developments in the period. Investors must register in advance for the live call.

Two MRI-guided platforms drive the commercial portfolio

Profound markets TULSA-PRO, which is FDA-cleared in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. The system is also cleared in Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the UAE.

Toronto – October 12, 2026 -- Men treated with whole-gland TULSA Procedure showed no median change in penile length at one month, compared with a median 0.65 cm reduction after robotic radical prostatectomy (RP), according to new data from the Level 1 CAPTAIN randomized controlled trial, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced.

Mixed-effects model shows 0.42 cm between-arm difference

The between-arm difference in change in penile length, estimated from a mixed-effects model, was 0.42 cm (p<0.001), which Profound describes as statistically significant. Xiaosong Meng, MD, PhD, Assistant Professor in the Department of Urology at UT Southwestern Medical Center, presented the results at the Society of Robotic Surgery Annual Meeting in Fort Lauderdale, Florida.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) cut its second-quarter 2026 net loss 39% to about $9.5 million, or $0.26 per share, from $15.7 million, or $0.52 per share, a year earlier. Operating expenses fell 16% to about $13.0 million, and the company reiterated its full-year revenue guidance of about $25.0 million.

Shipment delay pushes $3.1 million of TULSA revenue into July

Q2 revenue was about $2.5 million, up 12% year over year. Recurring non-capital revenue from single-use devices and extended-warranty services contributed $1.6 million, and capital equipment sales added $871,000.

About $3.1 million of TULSA product shipments expected in the final week of June went out in July and will be recognized in Q3. Excluding the delay, Q2 revenue would have been about $5.6 million, or 153% growth. The company attributes the slip to a logistics issue, not weaker demand, and says the issue is resolved.

Toronto – – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) replaced its chief financial officer effective immediately, promoting Corporate Controller Matthew Sobczyk to Interim CFO after Rashed Dewan stepped down from the role.

Sobczyk, a 2020 hire, takes over the finance function

Sobczyk first joined the interventional MRI (iMRI) company in 2020 and moves up from Corporate Controller. The company did not name a permanent successor or give a timeline for a CFO search.

Dewan stays on a short-term consulting contract

Dewan will remain with Profound under a short-term consulting contract to support the handover. CEO and Chairman Arun Menawat thanked him for his years of service and his contributions to the company.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has introduced new Treatment Delivery Console (TDC) software that it says provides a roadmap for surgeons to perform up to six TULSA Procedures per system per day, up from a reported maximum of four among a few physicians today.

Software rolls out across the TULSA-PRO installed base

The update is being deployed across Profound's TULSA-PRO installed base. It builds on earlier TULSA-AI modules aimed at raising procedural efficiency, improving physician experience and reducing planning complexity.

The release adds two feature sets. The first is real-time interventional MRI (iMRI) control. The second is a package of physician-requested improvements to the user interface and hardware control. Profound says both are designed to further increase TULSA Procedure efficiency and support regional ablation of tissue for a variety of prostate indications.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has appointed Richard Fabian, a medical imaging executive with more than 29 years of experience, as President, effective immediately, as the company moves its previous President into a newly created Chief Technology Officer role.

Fabian succeeds Mathieu Burtnyk, who becomes Chief Technology Officer

Fabian replaces Mathieu Burtnyk, PhD, who shifts to the newly created CTO position. Burtnyk invented the patented closed-loop temperature feedback control algorithm used by the TULSA-PRO platform. He has also led the scientific design and execution of all of the company's clinical studies for the technology, including the ongoing Level 1 post-market CAPTAIN randomized controlled trial.